VC: Investing preapproval too risky

An interview with med tech VC investor Dave Eichler of Psilos explores the current venture investing landscape in the sector. He said his firm is focused on growth capital for medical device companies and no longer seeks to invest preapproval. Psilos used to invest in early-stage med tech but doesn't any longer since the risk/reward calculation wasn't making sense. The firm also focuses on technology that can lower the cost and improve the quality of healthcare. Molecular breast imaging is of particular interest to Eichler currently. More

Suggested Articles

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

The respiratory care company Vyaire Medical has brought on a new CEO, Gaurav Agarwal, following a year of new product launches.